Business Description
Verve Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US92539P1012
Description
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 8.23 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.13 | |||||
| Debt-to-EBITDA | -0.34 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 0.72 | |||||
| Beneish M-Score | 0.65 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -36 | |||||
| 3-Year EPS without NRI Growth Rate | -25.8 | |||||
| 3-Year FCF Growth Rate | -23.1 | |||||
| Future 3-5Y Total Revenue Growth Rate | 7.62 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.34 | |||||
| 9-Day RSI | 27.98 | |||||
| 14-Day RSI | 28.18 | |||||
| 6-1 Month Momentum % | -46.72 | |||||
| 12-1 Month Momentum % | -61.18 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 19.82 | |||||
| Quick Ratio | 19.82 | |||||
| Cash Ratio | 19.38 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -23.2 | |||||
| Shareholder Yield % | -56.36 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1381.45 | |||||
| Net Margin % | -1226.43 | |||||
| FCF Margin % | -933.87 | |||||
| ROE % | -37.6 | |||||
| ROA % | -29.63 | |||||
| ROIC % | -167.08 | |||||
| ROC (Joel Greenblatt) % | -204.8 | |||||
| ROCE % | -35.18 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 24.19 | |||||
| PB Ratio | 0.75 | |||||
| Price-to-Tangible-Book | 0.75 | |||||
| EV-to-EBIT | 0.43 | |||||
| EV-to-Forward-EBIT | -2.92 | |||||
| EV-to-EBITDA | 0.45 | |||||
| EV-to-Forward-EBITDA | -3 | |||||
| EV-to-Revenue | -5.99 | |||||
| EV-to-Forward-Revenue | 0.15 | |||||
| EV-to-FCF | 0.64 | |||||
| Price-to-Net-Current-Asset-Value | 0.93 | |||||
| Price-to-Net-Cash | 0.95 | |||||
| Earnings Yield (Greenblatt) % | 232.56 | |||||
| FCF Yield % | -34.33 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VERV
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Verve Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 16.049 | ||
| EPS (TTM) ($) | -2.87 | ||
| Beta | 0 | ||
| Volatility % | 103.78 | ||
| 14-Day RSI | 28.18 | ||
| 14-Day ATR ($) | 0.462699 | ||
| 20-Day SMA ($) | 5.8415 | ||
| 12-1 Month Momentum % | -61.18 | ||
| 52-Week Range ($) | 4.9 - 21.4199 | ||
| Shares Outstanding (Mil) | 83.97 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Verve Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Verve Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Verve Therapeutics Inc Frequently Asked Questions
What is Verve Therapeutics Inc(VERV)'s stock price today?
The current price of VERV is $5.20. The 52 week high of VERV is $21.42 and 52 week low is $4.90.
When is next earnings date of Verve Therapeutics Inc(VERV)?
The next earnings date of Verve Therapeutics Inc(VERV) is 2024-08-09 Est..
Does Verve Therapeutics Inc(VERV) pay dividends? If so, how much?
Verve Therapeutics Inc(VERV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers